Clinical Trial Update: A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) [Phase 1, Phase 2]

View source ↗

Summary

AstraZeneca's Dato-DXd is being studied in a Phase 1/2 trial (TROPION-PanTumor02) in Chinese patients with advanced non-small cell lung cancer and triple-negati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-13